Anthony A. Rayner

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Michael T. Lotze, Yvedt L. Matory, Stephen E. Ettinghausen et al. · The Journal of Immunology · 1985 · 614 citations

Life Sciences, Immunology, Pharmacology +9

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.

David C. Hohn, Robert Stagg, Michael Friedman et al. · Journal of Clinical Oncology · 1989 · 455 citations

Medicine, Oncology, Pharmacology +17

Clinical effects and toxicity of interleukin-2 in patients with cancer

Michael T. Lotze, Yvedt L. Matory, Anthony A. Rayner et al. · Cancer · 1986 · 358 citations · Full text

Life Sciences, Immunology, Oncology +13

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Kim Margolin, Anthony A. Rayner, Michael Hawkins et al. · Journal of Clinical Oncology · 1989 · 349 citations

Pharmacy, Immunology, Oncology +17

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.

Brett T. Gemlo, Michael A. Palladino, Howard S. Jaffe et al. · PubMed · 1988 · 199 citations

Life Sciences, Immunology, Oncology +17